TABLE 4.
Predictors of T-Size reduction
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| Age (Years) | 0.993 | 0.963, 1.023 | 0.631 | |||
| Sex (Female) | 1.804 | 1.000, 3.255 | 0.050 | 1.887 | 0.998, 3.566 | 0.051 |
| ASA Class | 1.410 | 0.717, 2.773 | 0.319 | |||
| BMI (Kg/m2) | 1.012 | 0.958, 1.068 | 0.674 | |||
| Prior Abdominal Surgery | 1.384 | 0.770, 2.489 | 0.278 | |||
| Pre-operative Albumin (g/dL) | 1.072 | 0.591, 1.945 | 0.819 | |||
| CCI Age Unadjusted | 1.035 | 0.743, 1.442 | 0.839 | |||
| NT Cycle Number | 1.207 | 1.046, 1.393 | 0.010 | 1.137 | 0.973, 1.330 | 0.107 |
| Type of NT (Gem vs 5FU) | 1.672 | 0.839, 3.333 | 0.144 | |||
| Pre-NT CA19-9 (IU/mL) | 1.0001 | 0.9999, 1.0002 | 0.110 | |||
| Post-NT CA19-9 (IU/mL) | 0.9998 | 0.999, 1.0004 | 0.456 | |||
| Percent Change in CA19-9 | 0.187 | 0.064, 0.544 | 0.002 | |||
| CA19-9 Response ≥85% | 2.760 | 1.515, 5.027 | 0.001 | 2.401 | 1.268, 4.545 | 0.007 |
| Anatomic Type | ||||||
| Resectable | 1 | 1 | ||||
| Borderline Resectable | 2.148 | 1.104, 4.177 | 0.024 | 1.964 | 0.934, 4.129 | 0.075 |
| Locally Advanced | 0.938 | 0.306, 2.871 | 0.910 | 1.015 | 0.300, 3.432 | 0.981 |
Abbreviations: BMI: body mass index (in Kg/m2); CCI: Charlson comorbidity index; ASA: American society of anesthesiology class; NT: neoadjuvant chemotherapy; Gem: Gemcitabine based chemotherapy; 5-FU: 5-Fluorouracil based chemotherapy.